>
Akcea Therapeutics Inc logo

AKCA - Akcea Therapeutics Inc Share Price

$18.17 0.0  0.0%

Last Trade - 09/10/20

Sector
Healthcare
Size
Micro Cap
Market Cap £n/a
Enterprise Value £n/a
Revenue £239.5m
Position in Universe th / 6849
Bullish
Bearish
Unlock AKCA Revenue
Momentum
Relative Strength (%)
1m +1.68%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 43.4 64.9 488.5 107.6 129.4
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 June 2020, AkceaTherapeutics Inc revenues decreased 80% to $38.5M. Net lossbefore extraordinary items increased from $10.1M to $94.1M.Revenues reflect Research and development and licenserevenue under segment decrease of 96% to $6.9M. Higher netloss reflects Net loss share from commercial activitiedecrease of 49% to $10.5M (income), Selling/General/Admin.E increase of 2% to $70.4M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

AKCA Revenue Unlock AKCA Revenue

Net Income

AKCA Net Income Unlock AKCA Revenue

Normalised EPS

AKCA Normalised EPS Unlock AKCA Revenue

PE Ratio Range

AKCA PE Ratio Range Unlock AKCA Revenue

Dividend Yield Range

AKCA Dividend Yield Range Unlock AKCA Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
AKCA EPS Forecasts Unlock AKCA Revenue
Profile Summary

Akcea Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. The Company's drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc. (Ionis). The Company's volanesorsen drug has completed a Phase III clinical program for the treatment of familial chylomicronemia syndrome (FCS) and is currently in Phase III clinical development for the treatment of familial partial lipodystrophy (FPL). The Company's clinical pipeline contains drugs with the potential to treat inadequately addressed lipid disorders beyond elevated LDL-C that are contributing to the dramatic increase in the incidence of cardiometabolic disease, such as elevated triglycerides, oxidized phospholipids and other lipoproteins, such as lipoprotein(a), or Lp(a).

Directors
Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated December 22, 2014
Public Since July 14, 2017
No. of Shareholders: 11
No. of Employees: 294
Sector Healthcare
Industry Pharmaceuticals
Index
Exchange NASDAQ Global Select Market
Shares in Issue 101,615,491
Free Float (0.0%)
Eligible for
ISAs
SIPPs
AKCA Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for AKCA
Upcoming Events for AKCA
Frequently Asked Questions for Akcea Therapeutics Inc
What is the Akcea Therapeutics Inc share price?

As of 09/10/20, shares in Akcea Therapeutics Inc are trading at $18.17, giving the company a market capitalisation of £n/a. This share price information is delayed by 15 minutes.

How has the Akcea Therapeutics Inc share price performed this year?

Shares in Akcea Therapeutics Inc are currently trading at $18.17 and the price has moved by -7.58% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Akcea Therapeutics Inc price has moved by -35.11% over the past year.

What are the analyst and broker recommendations for Akcea Therapeutics Inc?

Of the analysts with advisory recommendations for Akcea Therapeutics Inc, there are there are currently 0 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Akcea Therapeutics Inc is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Akcea Therapeutics Inc next release its financial results?

Akcea Therapeutics Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Akcea Therapeutics Inc dividend yield?

Akcea Therapeutics Inc does not currently pay a dividend.

Does Akcea Therapeutics Inc pay a dividend?

Akcea Therapeutics Inc does not currently pay a dividend.

When does Akcea Therapeutics Inc next pay dividends?

Akcea Therapeutics Inc does not currently pay a dividend.

How do I buy Akcea Therapeutics Inc shares?

To buy shares in Akcea Therapeutics Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Akcea Therapeutics Inc?

Shares in Akcea Therapeutics Inc are currently trading at $18.17, giving the company a market capitalisation of £n/a.

Where are Akcea Therapeutics Inc shares listed? Where are Akcea Therapeutics Inc shares listed?

Here are the trading details for Akcea Therapeutics Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: AKCA
What kind of share is Akcea Therapeutics Inc?

We were not able to load our ranking data for Akcea Therapeutics Inc

Is there a Akcea Therapeutics Inc share price forecast 2021?

We were not able to load any forecast data for Akcea Therapeutics Inc.

How can I tell whether the Akcea Therapeutics Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Akcea Therapeutics Inc. Over the past six months, the relative strength of its shares against the market has been -0.13%. At the current price of $18.17, shares in Akcea Therapeutics Inc are trading at % against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Akcea Therapeutics Inc PE Ratio?

We were not able to find PE ratio data for Akcea Therapeutics Inc.

Who are the key directors of Akcea Therapeutics Inc?

We were unable to find the directors for Akcea Therapeutics Inc.

Who are the major shareholders of Akcea Therapeutics Inc?

Here are the top five shareholders of Akcea Therapeutics Inc based on the size of their shareholding:

Ionis Pharmaceuticals Inc Corporation
Percentage owned: 75.87% (77.1m shares)
Fidelity Management & Research Company LLC Investment Advisor
Percentage owned: 10.44% (10.6m shares)
Novartis Pharma AG Corporation
Percentage owned: 6.15% (6.25m shares)
Fidelity Growth Company Fund Mutual Fund
Percentage owned: 4.8% (4.88m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 2.09% (2.13m shares)
Similar to AKCA
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.